These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18055312)

  • 1. [Randomised phase II trials in oncology].
    Piedbois P
    Bull Cancer; 2007 Nov; 94(11):953-6. PubMed ID: 18055312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
    Mayo MS; Mahnken JD; Soong SJ
    J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
    Sharma MR; Maitland ML; Ratain MJ
    Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II trials: misleading and unreliable.
    Stewart DJ
    J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
    [No Abstract]   [Full Text] [Related]  

  • 7. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
    Ratain MJ; Karrison TG
    Clin Cancer Res; 2007 Feb; 13(3):781-2. PubMed ID: 17289865
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimal two-stage randomized multinomial designs for Phase II oncology trials.
    Sun LZ; Chen C; Patel K
    J Biopharm Stat; 2009; 19(3):485-93. PubMed ID: 19384690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phases 0, 1 and 2 oncology clinical trials: current questions].
    Penel N; Fournier C; Stéphanie C
    Bull Cancer; 2010 Jan; 97(1):55-63. PubMed ID: 20080458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trials with a prospective control.
    Jung SH
    Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
    Zhang Y; Mietlowski W; Chen B; Wang Y
    J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities.
    Lienhardt C; Davies G
    Int J Tuberc Lung Dis; 2010 May; 14(5):528-37. PubMed ID: 20392344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New trends in assessment in anticancer treatments by phase II clinical trials].
    Medioni JR; Rycke YD; Asselain B
    Bull Cancer; 2000 Jul; 87(7-8):551-6. PubMed ID: 10969213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
    Mazumdar M; Fazzari M; Panageas KS
    Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Other paradigms: randomized discontinuation trial design.
    Stadler W
    Cancer J; 2009; 15(5):431-4. PubMed ID: 19826364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomization in Phase II Clinical Trials.
    Yothers G; Wieand S; Freireich EJ
    Clin Adv Hematol Oncol; 2006 Oct; 4(10):776-8. PubMed ID: 17111561
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.